89 results about "Osteopoikilosis" patented technology

Method and devices are provided for extended and controlled delivery of parathyroid hormone to a patient. The method includes implanting a medical device into the patient, the medical device comprising a substrate, a plurality of reservoirs in the substrate, a release system contained in each of the reservoirs, wherein the release system comprises parathyroid hormone; and controllably releasing a pharmaceutically effective amount of the parathyroid hormone from the reservoirs. The parathyroid hormone can be released intermittently, such as once daily over an extended period (e.g., two months, ten months, or more.). The device can further include reservoirs containing a bone resorption inhibitor or other drug for release. The devices are useful in delivering PTH for the treatment and prevention of bone loss, such as associated with osteoporosis.

A method and system for detection and tracking of osteoporosis is disclosed. A method of characterizing an image of a target vertebra includes building a computer model from a set of sample images of pathological and non-pathological variations of vertebrae representing variations in shape of the vertebrae. The method also includes receiving an image of a target vertebra of a subject and automatically estimating contours of lateral outlines of the superior and the inferior cortical endplates of the image. The parameters of the model are varied to determine a set that represents a model shape that approximates the estimated contours of the outlines of the cortical endplates. The method includes automatically characterizing the target vertebra based on the set of model parameters that are determined and outputting on a display device the characterization of the target vertebra.

Osteoporosis may be detected in-vivo by applying an acoustic sensor in contact with the skin of the patient while subjecting the patient to stress, for example, by lifting light weights and measuring the acoustic emissions sensed by the acoustic sensor to provide an indication of the degree of osteoporosis damage incurred by the bones of the patient being diagnosed.

A method for providing electromagnetic therapy to a patient includes placing the patient in proximity to an electromagnetic therapy apparatus. The electromagnetic therapy apparatus includes an electrical circuit for generating an electrical drive signal, a first transducer coil and a second transducer coil for generating respective electromagnetic fields in response to the drive signal, a first portion with a configuration corresponding generally with a chair seat, and a second portion with a configuration corresponding generally with a chair back. The first transducer coil is disposed within the first portion and the second transducer coil is disposed within the second portion. The method further includes stimulating the patient with a pulsed electromagnetic field from at least the first and second transducer coils. The pulsed electromagnetic field having a number of pulses, each pulse having a pulse period of ten microseconds to twenty microseconds.

The invention provides polynucleotides and polypeptides that are co-expressed with genes known to be involved in bone remodeling and osteoporosis. The invention also provides expression vectors, host cells, and methods for making a polypeptide, for screening or purifying ligands, and for diagnosing disorders associated with bone remodeling or osteoporosis.

The invention discloses a new application of medicines or foods for preventing and curing the osteoporosis, relating to the technical field of medicines, wherein the medicines or foods for preventing and curing the osteoporosis are prepared by taking a vital energy benefiting and smart decoction as a main raw material, and the vital energy benefiting and smart decoction is prepared from ginseng or codonopsis pilosula, astragalus root, bugbane, roots of kudzu vine, fructus viticis, radix paeoniae alba, corktree and liquorice. Furthermore, the invention also relates to a new application of medicines or foods for preventing and curing the osteoporosis, wherein the medicines or foods for preventing and curing the osteoporosis are prepared by taking the adding or subtracting formula of the vital energy benefiting and smart decoction or a pharmaceutical composition prepared under the principle of the vital energy benefiting and smart decoction formula as main raw materials. Each raw material medicine can be singly powdered and then mixed, or mixed and then powdered for being directly processed to prepare oral preparation; and the raw material medicines can be singly extracted and then mixed, or mixed firstly and then extracted, to prepare any common pharmaceutical formulation with pharmaceutically acceptable accessories, such as pills, powders, capsules, tablets, medicinal granules, oral liquid and the like.

The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.

The invention provides a non-invasive detection kit for detecting susceptible genes of women osteoporosis. The kit comprises five osteoporosis single nucleotide polymorphism genotype specific primers, a DNA sequencing primer, a polymerase chain reaction (PCR) reaction component, a PCR product purification component, a DNA sequencing reaction component and the like, wherein the five osteoporosis single nucleotide polymorphism genotype specific primers are used for detecting G-174C on an IL-6 gene, BsmI and TaqI on a VDR gene, G-308A on a TNF-a and Lys3Asn on an OPG gene. The kit can screen out high-risk women group susceptible to osteoporosis by detecting the genotypes of the five osteoporosis single nucleotide polymorphisms closely related to osteoporosis, can evaluate the risk level susceptible to osteoporosis from gene level according to the gene detection result of every checked person and can guide menopausal women to effectively prevent osteoporosis.

The invention discloses a molecular marker which utilizes a PIGK gene to carry out osteoporosis early diagnosis. With the adoption of a method using a gene chip and QPCR (Quantitative Polymerase Chain Reaction), when blood of normal people and blood of osteoporosis patients have remarkable difference, whether tested people have osteoporosis or not can be judged through detecting an expression condition of the PIGK gene in the blood. According to the correlation of the gene chip and the QPCR, the invention develops a kit for diagnosing the osteoporosis; the kit is used for diagnosing the osteoporosis through detecting the expression of the PIGK gene. The diagnosis kit provided by the invention can be used for early diagnosis of diseases and has a wide clinical application prospect.

The present invention relates to methods and materials used to express the HBM protein in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

A bone cement conductor device provides for the application and the safe and effective filling of bone cement during surgical treatment procedures in patients suffering from osteoporosis. More specifically, the device is constituted by a structure that is easy to manufacture and handle, and that facilitates surgical processes and treatments, demanding less effort of surgeons. The device includes an outer encasement with a conductor body being provided with interlink and connection mechanisms with a cement injection device and a bone screw that eliminate any risk of leakage or incorrect application of the cement in the patient's bones.

A method of measuring Bone Mineral Density (BMD) including providing a model of a plurality of constituents of at least a portion of a subject body, the model including at least one bone constituent, injecting electric current into the portion of the subject body using a current injection electrode, such that at least part of the current flows through the at least one bone constituent, measuring a value of electric potential at a surface of the subject body using a pickup electrode, using a value of the injected electric current as input to a model of the at least a portion of a subject body, and calculating a value of conductance of the bone constituent corresponding to a value of the injected electric current and the measured value of the electric potential. Related apparatus and methods are also described.

The invention discloses a ligustrum lucidum and the new use for Chinese medicine of a ligustrum lucidum extractive for preparing medicines for prevention or treatment of osteoporosis, and also discloses a granule for prevention or treatment of osteoporosis, wherein, the granule comprises 25 to 35 percents of the ligustrum lucidum extractive and 65 to 75 percents of an excipient which chooses sucrose and dextrine, or is made into capsules. The capsules contain the ligustrum lucidum extractive. The ligustrum lucidum single-taste and the relative pharmaceutical preparation of the invention has the advantages of accurate curative effect, low side effects, more drug safety, simple preparation craft and lower cost in the application of prevention or treatment of osteoporosis.

A medicine for treating various diseases such as women's climacteric syndrome, osteoporosis, mental depression, premature ovarian failure, premenstrual tension syndrome, hyperthyroidism, male and female infertility, hair loss and white hair, and is characterized in that it It is composed of fatty acids in the following weight percent range: hexadecanoic acid 8-32%, hexadecenoic acid 11-35%, octadecenoic acid 13-33%, octadecanoic acid 0.3-2.5%, octadecanoic acid Carbadienoic acid 11-33%, octadecatrienoic acid 3-15%. Compared with other drugs, the drug composition is simple, belongs to the target organ agonist, and has an independent reversible regulation function on the second messenger of the body. It is a medicine with high curative effect, safety and simplification.

A medicinal puerarin composition used for preparing the medicine to treat the cardiovascular and cerebrovascular diseases and osteoporosis is prepared from puerarin and solubilizing agent chosen from hydroxy propyl-beta-cyclodextrin, beta-cyclodextrin and hydroxyethyl-beta-cyclodextrin. It has high water-solubility.

The invention discloses an ultrasonic CT imaging method of bone broad-band attenuation (BUA) detected by non-diffraction ultrasound, which is characterized by the following: adopting non-diffraction ultrasonic field as launching field to pierce bone; obtaining BUA parameter through fitful mathematical and physical method; reconstructing BUA cut image of bone through CT imaging technique; selecting Bessel ultrasonic field or X-wave ultrasonic field as non-diffraction ultrasonic field; improving imaging distinguishability with low cost effectively.

The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors.

The invention discloses GM2A genes as a molecular marker for male osteoporosis diagnosis or prognosis. Through high throughput sequencing and QPCR studies, content of the GM2A genes in the blood of male osteoporosis patients is significantly less than that in normal males so that the GM2A genes can be used as a molecular marker for the male osteoporosis diagnosis or prognosis. A method of using the content of gene expression products in the blood to represent osteoporosis can be used for screening healthy people, and effectively prevent the osteoporosis.

The invention discloses use of epimedin C in preparing medicament for treating osteoporosis. In examination, under equal dosage, effect of the epimedin C is better than that of epimedium, epimedum total flavone and icariin, and the epimedin C can be used for preparing medicament for treating osteoporosis. Compared with the prior art, under equal dosage, effect of the epimedin C is better than that of epimedium, epimedum total flavone and icariin in treating osteoporosis, and effect of compound medicament of the epimedin C and other medicament (such as estrogen) is better than that of compound medicament of epimedum total flavone and same medicament. Under equal dosage, active component of the epimedin C is higher, and the invention provides a medicament selection with better curative effect for treating osteoporosis.

The invention provides a novel bone-target nano-particle with high affinity and a method for preparing the novel bone-target nano-particle. The novel bone-target nano-particle comprises PLGA-PEG-COOHpolymer medicine carriers, a bone-target substance tetracycline and hydrophobic medicines. The novel bone-target nano-particle and the method for preparing the novel bone-target nano-particle with thehigh affinity have the advantages that PLGA-b-PEG-COOH polymers can be generated by polymers PLGA-COOH and NH2-PEG-COOH under the effects of EDC / NHS catalysts, surface modification is carried out bythe tetracycline, carriers have bone tissue target performance by the aid of the bone deposition ability of the tetracycline, and accordingly anti-osteoporosis medicines can be effectively delivered to bone tissues; the carriers have the bone tissue target performance by the aid of the bone deposition ability of the tetracycline, and accordingly the anti-osteoporosis medicines can be effectively delivered to the bone tissues.

The invention provides a compound preparation for preventing and treating the osteoporosis and a preparation method thereof. The compound preparation consists of herba epimedii, radix achyranthis bidentatae, calcium citrate, casein phosphopeptides and magnesium stearate. The preparation method comprises the following steps: preparing powder by extracting the materials of the herba epimedii and the radix achyranthis bidentatae, sieving the calcium citrate, the casein phosphopeptides and the magnesium stearate, blending, mixing, granulating, metering, filling into capsules and packaging. The compound preparation and the preparation method provided by the invention have the advantages that elaborate prescription is adopted on the basis of the traditional theory of traditional Chinese medicine and the modern pharmacological research, the herba epimedii and the radix achyranthis bidentatae have the effects of nourishing liver and kidney and strengthening the muscles and bones; and by combination of the casein phosphopeptides and the calcium citrate, the absorption and utilization of calcium can be better enhanced, the calcium content in bones can be improved and the density of the bones can be increased, so that the two effects of increasing the density of the bones and preventing and treating the osteoporosis are achieved. A product prepared by the compound preparation not only is safe in administration and has obvious preventing and treating effects and health-care effect, but also is low in industrial production cost and has a good prospect for market development and application.

The invention discloses a Chinese medicinal compound prescription having an effect of resisting osteoporosis. The Chinese medicinal compound comprises the following components in part by weight: 12 to 25 parts of astragalus, 10 to 20 parts of rehmanniae vaporata, 10 to 18 parts of indian buead, 12 to 25 parts of Chinese yam rhizome, 10 to 35 parts of tuber fleece flower root, 12 to 25 parts of epimedium herb, 10 to 20 parts of common macrocarpium fruit, 12 to 25 parts of glossy privet fruit, 12 to 20 parts of yerbadetajo herba ecliptae, and 12 to 20 parts of lentil. The invention also discloses a preparation method and application of the Chinese medicinal compound prescription having the effect of resisting the osteoporosis. The Chinese medicinal compound prescription having the effect of resisting the osteoporosis comprises the raw materials which are selected according to a traditional Chinese medicine theory and the nosogenesis of the osteoporosis and are blended together, all the components have scientific and reasonable proportioning, and clinical observations and researches show that the Chinese medicinal compound prescription has the effects of strengthening the spleen and replenishing qi, and nourishing kidney and replenishing essence, has the function of preventing and treating the osteoporosis, and has no adverse reaction for long-term use.